(Q35778581)

10 August 2017

1 reference

title

Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials (English)

1 reference

10 August 2017

1 reference

Moneeb Ehtesham

1

1 reference

10 August 2017

Keith L Black

series ordinal

2

1 reference

10 August 2017

John S Yu

series ordinal

3

1 reference

10 August 2017

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

11

1 reference

10 August 2017

3

1 reference

10 August 2017

192-207

1 reference

Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality.

10 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Brain tumor survival: results from the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Glioblastoma multiforme: pathology, natural history and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Imbalances in T cell subpopulations in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Effects of glioma cells on maturation of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Malignant glioma modulation of immune function: relative contribution of different soluble factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Expression of the GM1-species, [NeuN]-GM1, in a case of human glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Occurrence of ganglioside GD3 in neoplastic astrocytes. An immunocytochemical study in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Selective expression of interleukin-10 gene within glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Monoclonal antibody therapy of human gliomas: current status and future approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

The 200/220 kDa antigen recognized by monoclonal antibody (MAb) UJ127.11 on neural tissues and tumors is the human L1 adhesion molecule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Immunotherapy with autologous white cell infusions (“lymphocytes”) in the treatment of recurrent glioblastoma multiforme.A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Clinical studies of intrathecal autologous lymphocyte infusions in patients with malignant glioma: A toxicity study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Intrathecal injection of autologous leucocytes in glioblastoma: circulatory dynamics within the subarachnoid space and clinical results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Immunotherapy of glioblastoma with intratumoural administration of autologous lymphocytes and human lymphoblastoid interferon. A further clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a childrens cancer group phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Clinical effect of interferon in malignant brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Interleukin-12-based immunotherapy against rat 9L glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Pharmacological elements in clinical application of synthetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Human U251MG glioma cells expressing the membrane form of macrophage colony-stimulating factor (mM-CSF) are killed by human monocytes in vitro and are rejected within immunodeficient mice via paraptosis that is associated with increased expression o

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Gene therapy of experimental brain tumors using neural progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Cancer vaccines and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100307

10.1177/107327480401100307

21 January 2018

Identifiers

DOI

0 references

1 reference